CAY10566
Based on 18 publication(s) in Google Scholar
CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.93%
- CAS No.: 944808-88-2
- 화학식: C18H17ClFN5O2
- 분자량:389.81
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Orally Active Compound Library
HY-L061
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Lipid Metabolism Compound Library
HY-L091
-
Heterocyclic Compound Library
HY-L138
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
Publications Citing Use of MedChemExpress (MCE) CAY10566
More- Cancer Cell. 2026 Feb 9;44(2):383-404.e18. [Abstract]
- Gastroenterology. 2024 May;166(5):772-786.e14. [Abstract]
- Nat Commun. 2021 May 17;12(1):2869. [Abstract]
- Redox Biol. 2021 Jan:38:101807. [Abstract]
- Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203480119. [Abstract]
- Regen Biomater. 2025 Jun 16:12:rbaf056. [Abstract]
- Free Radic Biol Med. 2024 Sep:222:229-243. [Abstract]
- Anal Chem. 2026 Jan 27;98(3):2401-2413. [Abstract]
- Mol Cancer Ther. 2025 Jun 4;24(6):920-930. [Abstract]
- J Ethnopharmacol. 2026 Feb 28:357:120890. [Abstract]
- J Agric Food Chem. 2020 Oct 28;68(43):12058-12066. [Abstract]
- Brain Res Bull. 2025 Dec 20:111693. [Abstract]
- Cancer Res Commun. 2023 Jun 20;3(6):1067-1077. [Abstract]
- Toxicol Appl Pharmacol. 2024 Jan:482:116788. [Abstract]
- Exp Eye Res. 2026 May:266:110932. [Abstract]
- bioRxiv. 2026 Feb 1.
- bioRxiv. 2025 Aug 06.
- Research (Wash D C). 2023:6:0087. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
Biological Activity
IC50: 4.5 nM (SCD1 in mouse), 26 nM (SCD1 in human)[2]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H1155 | IC50 |
<10 nM
Compound: 4
|
Inhibition of SCD in human NCI-H1155 cells non-expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay
Inhibition of SCD in human NCI-H1155 cells non-expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay
|
[PMID: 32787093] |
| NCI-H2122 | IC50 |
<10 nM
Compound: 4
|
Inhibition of SCD in human NCI-H2122 cells expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay
Inhibition of SCD in human NCI-H2122 cells expressing CYP4F11 assessed as reduction in cell viability incubated for 96 hrs by cell titer Glo reagent based assay
|
[PMID: 32787093] |
CAY10566 (0.0001-10 μM; 24 hours) concentration-dependently decreases Swiss 3T3 cell proliferation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Swiss 3T3 cells
-
Concentration:0.0001, 0.001, 0.01, 0.1, 1, 10 μM
-
Incubation Time:24 hours
-
Result:Swiss 3T3 cell proliferation was concentration-dependently decreased.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 944808-88-2
-
Appearance Solid
-
분자량 389.81
-
화학식 C18H17ClFN5O2
-
Color White to yellow
-
SMILES
CC1=NN=C(C2=NN=C(N3CCC(OC4=CC(F)=CC=C4Cl)CC3)C=C2)O1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (18)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma. [Abstract]2026 Feb 9;44(2):383-404.e18. PMID: 41544627 -
Gastroenterology
2024 May;166(5):772-786.e14. PMID: 38272100 -
Nat Commun
2021 May 17;12(1):2869. PMID: 34001877 -
Redox Biol
FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. [Abstract]2021 Jan:38:101807. PMID: 33271455
CAY10566 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2021 Jan:38:101807. [Abstract]
FBW7 silencing PANC-1 and SW1990 cells were treated with RSL3 (2 μmol/L) or CAY10566 (5 μmol/L) for 48–72 h and then detected cell viability.
CAY10566 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2021 Jan:38:101807. [Abstract]
TEM imaging was conducted in FBW7T205A overexpressed PANC-1 cells. RSL3 (2 μmol/L) and CAY10566 (5 μmol/L) treated PANC-1 cells functioned as the positive control. Red arrows showed the shrunken mitochondria. Blue arrows showed lipid droplets. The values below the western blot band represent the relative mean gray values of three independent experiments. Gray values were calculated by Adobe Photoshop CS6.
-
Proc Natl Acad Sci U S A
Ovarian cancer cell fate regulation by the dynamics between saturated and unsaturated fatty acids. [Abstract]2022 Oct 11;119(41):e2203480119. PMID: 36197994
CAY10566 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203480119. [Abstract]
XBP1 splicing in OVCAR-5 cells cultured in low-serum conditions and treated with SCD inhibitor CAY10566 (0-24.3 nM) for 48 h.
CAY10566 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203480119. [Abstract]
XBP1 splicing in primary cells from tumors of OC patients cultured in low-serum conditions and treated with 3 μM CAY10566 for 48 h or with 1 μM CAY10566 and 50 μM PA for 12 h.
CAY10566 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2203480119. [Abstract]
XBP1 splicing in OVCAR-5 cells cultured in medium containing low serum and treated with 21.6 nM CAY10566 and indicated doses of OA for 48 h.
-
Regen Biomater
Matrix stiffness boosts PDAC chemoresistance via SCD1-dependent lipid metabolic reprogramming. [Abstract]2025 Jun 16:12:rbaf056. PMID: 40741620 -
Free Radic Biol Med
Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]2024 Sep:222:229-243. PMID: 38906233 -
Anal Chem
13C-Isotope Tracing Structural Lipidomics for Resolving Phospholipid Metabolism Dynamics in Human Breast Cancer Cells. [Abstract]2026 Jan 27;98(3):2401-2413. PMID: 41512137 -
Mol Cancer Ther
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. [Abstract]2025 Jun 4;24(6):920-930. PMID: 39834305 -
J Ethnopharmacol
Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]2026 Feb 28:357:120890. PMID: 41232632 -
J Agric Food Chem
2020 Oct 28;68(43):12058-12066. PMID: 33052678 -
Brain Res Bull
Inhibition of SCD1 attenuates neuroinflammation and brain injury after cerebral ischemia-reperfusion. [Abstract]2025 Dec 20:111693. PMID: 41429330 -
Cancer Res Commun
2023 Jun 20;3(6):1067-1077. PMID: 37377614 -
Toxicol Appl Pharmacol
2024 Jan:482:116788. PMID: 38086441 -
Exp Eye Res
SREBP1-driven SCD1 protects retinal pigment epithelium from oxidative damage by activating the NRF2/GPX4 axis. [Abstract]2026 May:266:110932. PMID: 41720386 -
-
-
Research (Wash D C)
Metabolic Pathway of Monounsaturated Lipids Revealed by In-Depth Structural Lipidomics by Mass Spectrometry. [Abstract]2023:6:0087. PMID: 36951803
용액&용해도
DMSO : 25 mg/mL (64.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Acetone : 10 mg/mL (25.65 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.41 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Masuda M, et al. Activating transcription factor 4 regulates stearate-induced vascular calcification. J Lipid Res. 2012 Aug;53(8):1543-52. [Content Brief]
[2]. Liu G, et al. Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors. J Med Chem. 2007 Jun 28;50(13):3086-100. [Content Brief]
[3]. Koeberle A, et al. Palmitoleate is a mitogen, formed upon stimulation with growth factors, and converted to palmitoleoyl-phosphatidylinositol. J Biol Chem. 2012 Aug 3;287(32):27244-54. [Content Brief]
[4]. Kamphorst JJ, et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A. 2013 May 28;110(22):8882-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Acetone / DMSO | 1 mM | 2.5654 mL | 12.8268 mL | 25.6535 mL | 64.1338 mL |
| 5 mM | 0.5131 mL | 2.5654 mL | 5.1307 mL | 12.8268 mL | |
| 10 mM | 0.2565 mL | 1.2827 mL | 2.5654 mL | 6.4134 mL | |
| 15 mM | 0.1710 mL | 0.8551 mL | 1.7102 mL | 4.2756 mL | |
| 20 mM | 0.1283 mL | 0.6413 mL | 1.2827 mL | 3.2067 mL | |
| 25 mM | 0.1026 mL | 0.5131 mL | 1.0261 mL | 2.5654 mL | |
| DMSO | 30 mM | 0.0855 mL | 0.4276 mL | 0.8551 mL | 2.1378 mL |
| 40 mM | 0.0641 mL | 0.3207 mL | 0.6413 mL | 1.6033 mL | |
| 50 mM | 0.0513 mL | 0.2565 mL | 0.5131 mL | 1.2827 mL | |
| 60 mM | 0.0428 mL | 0.2138 mL | 0.4276 mL | 1.0689 mL |
CAY10566 Related Classifications
HY-15823 Related Classifications
Powered by Bioz